[HTML][HTML] Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy

F Xu, Y Gao, Y Wang, J Pan, J Sha, X Shao, X Kang… - Oncotarget, 2016 - ncbi.nlm.nih.gov
F Xu, Y Gao, Y Wang, J Pan, J Sha, X Shao, X Kang, J Qin, MJ You, Y Huang, B Dong…
Oncotarget, 2016ncbi.nlm.nih.gov
Patients with prostate cancer (PCa) have a variable prognosis. It is challenging to recognize
the progressive disease. In this study, we focused on TSPAN1, a new member of the
tetraspanin family. Its expression was decreased in progressive PCa and was an
independent prognosis factor of biochemical recurrence after radical prostatectomy. In vitro,
knockdown and overexpression of TSPAN1 in PCa cell lines showed that TSPAN1 could
inhibit cell proliferation and migration. TSPAN1 was positive related to PTEN in both clinical …
Abstract
Patients with prostate cancer (PCa) have a variable prognosis. It is challenging to recognize the progressive disease. In this study, we focused on TSPAN1, a new member of the tetraspanin family. Its expression was decreased in progressive PCa and was an independent prognosis factor of biochemical recurrence after radical prostatectomy. In vitro, knockdown and overexpression of TSPAN1 in PCa cell lines showed that TSPAN1 could inhibit cell proliferation and migration. TSPAN1 was positive related to PTEN in both clinical specimen and mouse models. The combination of these two markers could increase their prognosis value especially in low risk patients. In vitro TSPAN1 knockdown resulted in increased Akt phosphorylation and caused evident cell cycle transition from G1 to S phase. Our data suggests that TSPAN1 is a valuable marker to recognize more progressive PCa.
ncbi.nlm.nih.gov